Acorda Therapeutics, Inc. reported AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2017 of $166 million.

Unaudited 2017 full-year net sales were $542 million, an increase of approximately 10% from 2016.

The company provided AMPYRA guidance for 2018. AMPYRA net revenue is expected to be $330-$350 million. The company expects to maintain exclusivity of AMPYRA at least through July 30, 2018; this guidance is subject to change based on the appellate court's decision. R&D expenses for the full year 2018 are expected to be $100-$110 million and include manufacturing expenses associated with INBRIJA. SG&A expenses for the full year 2018 are expected to be $170-$180 million.